Clinical Trials Directory

Trials / Completed

CompletedNCT03307044

Fractional CO2 Laser Therapy for Survivors of Breast Malignancies

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
66 (actual)
Sponsor
Ohio State University Comprehensive Cancer Center · Academic / Other
Sex
Female
Age
Healthy volunteers
Not accepted

Summary

This pilot clinical trial studies how well fraction carbon dioxide (CO2) laser therapy works in treating vaginal atrophy in patients with breast cancer. Fraction CO2 laser therapy uses intense beams of light to cut, burn, or destroy tissue and may remodel vaginal tissue and direct controlled thermal damage of vaginal mucosa.

Detailed description

PRIMARY OBJECTIVES: I. To demonstrate the feasibility of fractionated CO2 laser treatments in patients with breast cancer with vaginal atrophy by determining treatment completion rates and tolerability of treatment. II. To demonstrate the efficacy of fractionated CO2 laser treatments in patients with breast cancer with vaginal atrophy as determined by improvement from baseline to post treatment in the score of the Vaginal Assessment Scale (VAS). SECONDARY OBJECTIVES: I. Sexual behavior/function as measured by the Sexual Experiences Scare, Global sexual satisfaction scale, Female Sexual Function Index (FSFI), and the Female Sexual Distress Scare (FSDS). II. Other symptoms of urogenital atrophy using the Urogenital Distress Inventory (UDI). III. Overall patient assessment of symptoms by Patient Global Impression of Improvement scale (PGI-I). OUTLINE: Patients undergo fractional CO2 laser therapy every 4-6 weeks for 3 treatments. After completion of study treatment, patients are followed up at 4 weeks.

Conditions

Interventions

TypeNameDescription
PROCEDURELaser TherapyUndergo fractional CO2 laser therapy
OTHERQuestionnaire AdministrationAncillary studies

Timeline

Start date
2017-11-16
Primary completion
2018-12-21
Completion
2022-05-05
First posted
2017-10-11
Last updated
2023-03-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT03307044. Inclusion in this directory is not an endorsement.